Gemini Therapeutics, Inc.

GMTXNASDAQHealthcare

$1.35

+$0.00(+0.00%)

Market Cap$25491780

P/E Ratio—

52W High$24.7

52W Low$1.35

Avg Volume19K

Open$1.36

Beta0.00

Overview

Gemini Therapeutics, Inc. (GMTX) Earnings: Dates, EPS & Revenue History

Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.

GMTX · earnings · updated Jun 9, 2026

Latest Earnings

Q3 FY2022Report Date: Aug 11, 2022

EPS Actual

-$1.60

Est. -$2.00 · +20.0%

Revenue

—

Fiscal Period

Q3 FY2022

FY ends December

Report Date

Aug 11, 2022

After Market Close

▲ Beat EPS✓ 1-Quarter EPS Beat Streak

GMTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.

Next Earnings Date

Days Away

days

Expected Date

Sep 1, 2026

Fiscal Period

Q3 FY2026

Release Time

◌ Time TBD (Unconfirmed)

EPS Est.

—

Days Away84

Expected DateSep 1, 2026

Fiscal PeriodQ3 FY2026

Release TimeTime TBD (Unconfirmed)

EPS Est.—

EPS & Revenue vs. Estimates

Actual (Beat)

Actual (Miss)

Estimated

Earnings History

Period	Report Date	EPS Est.	EPS Actual	EPS Surpr.	Revenue	Rev. Est.	Rev. Surpr.
◌ Q1 FY2023	Mar 8, 2023	—	—	—	—	—	—
◌ Q4 FY2022	Nov 10, 2022	—	—	—	—	—	—
▲ Q3 FY2022	Aug 11, 2022	-$2.00	-$1.60	+20.0%	—	—	—
▼ Q2 FY2022	May 6, 2022	-$3.01	-$3.50	-16.3%	—	—	—
▲ Q4 FY2021	Nov 15, 2021	-$4.73	-$4.30	+9.1%	—	—	—
▲ Q3 FY2021	Aug 12, 2021	-$4.00	-$3.80	+5.0%	—	—	—
▼ Q2 FY2021	May 13, 2021	-$3.65	-$5.90	-61.6%	—	—	—
◌ Q1 FY2021	Jan 19, 2021	—	—	—	—	—	—

Q1 FY2023

Mar 8, 2023

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q4 FY2022

Nov 10, 2022

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q3 FY2022

Aug 11, 2022Beat

EPS Actual

-$1.60

EPS Est.

-$2.00

EPS Surpr.

+20.0%

Revenue

—

Q2 FY2022

May 6, 2022Miss

EPS Actual

-$3.50

EPS Est.

-$3.01

EPS Surpr.

-16.3%

Revenue

—

Q4 FY2021

Nov 15, 2021Beat

EPS Actual

-$4.30

EPS Est.

-$4.73

EPS Surpr.

+9.1%

Revenue

—

Q3 FY2021

Aug 12, 2021Beat

EPS Actual

-$3.80

EPS Est.

-$4.00

EPS Surpr.

+5.0%

Revenue

—

Q2 FY2021

May 13, 2021Miss

EPS Actual

-$5.90

EPS Est.

-$3.65

EPS Surpr.

-61.6%

Revenue

—

Q1 FY2021

Jan 19, 2021

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

No analyst estimates available for GMTX.

Earnings Price Reaction

Closing price one trading day before vs. one trading day after each earnings release.

Period	Report Date	EPS Beat/Miss	Price Before	Price After	1D Reaction
▲ Q3 FY2022	Aug 11, 2022	+20.0%	$2.01	$1.93	-3.98%
▼ Q2 FY2022	May 6, 2022	-16.3%	$1.51	$1.49	-1.32%
▲ Q4 FY2021	Nov 15, 2021	+9.1%	$3.42	$3.58	+4.68%
▲ Q3 FY2021	Aug 12, 2021	+5.0%	$4.06	$4.15	+2.22%
▼ Q2 FY2021	May 13, 2021	-61.6%	$8.59	$8.62	+0.35%

Q3 FY2022-3.98%

Report Date

Aug 11, 2022

EPS Beat/Miss

+20.0%

Price Before

$2.01

Price After

$1.93

Q2 FY2022-1.32%

Report Date

May 6, 2022

EPS Beat/Miss

-16.3%

Price Before

$1.51

Price After

$1.49

Q4 FY2021+4.68%

Report Date

Nov 15, 2021

EPS Beat/Miss

+9.1%

Price Before

$3.42

Price After

$3.58

Q3 FY2021+2.22%

Report Date

Aug 12, 2021

EPS Beat/Miss

+5.0%

Price Before

$4.06

Price After

$4.15

Q2 FY2021+0.35%

Report Date

May 13, 2021

EPS Beat/Miss

-61.6%

Price Before

$8.59

Price After

$8.62

Avg Beat Reaction+0.97%

Avg Miss Reaction-0.49%

Beat Rate3 / 5 quarters

Largest Move+4.68% (Q4 FY2021)

Data: FMP /historical-price-eod/full · field: close

About Earnings & Data Methodology

Gemini Therapeutics, Inc. (GMTX) most recently reported earnings on August 11, 2022 for Q3 FY2022, posting EPS of $-1.60 — beating the analyst consensus of $-2.00 by +20.0%. The next GMTX earnings date is expected around September 1, 2026.

Each quarter, investors track GMTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GMTX revenue tab →

Earnings Glossary

EPS (Earnings Per Share)

Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.

Earnings Surprise %

(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.

Beat / Miss / In-Line

Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.

BMO / AMC

Before Market Open / After Market Close. Two windows when companies typically release results.

Fiscal Quarter

GMTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.

Analyst Consensus

Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.

Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.

Revenue Price history Financial statements Forecast Dividends Market cap

Frequently asked questions

GMTX earnings · 5 questions

Gemini Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. GMTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GMTX historically reports after market close (AMC).

GMTX earnings datewhen is GMTX earningsGMTX next earnings datewhen does GMTX report earningsGMTX earnings calendar

▸ Source: FMP · Gemini Therapeutics, Inc. SEC filings · US GAAP · Gemini Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026